ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.60
-0.34%
US Tech 100
17,650.00
0.05%
S&P 500
5,222.68
0.16%
US Dollar vs CAD
1.36775
0.00%
Bitcoin
61,031.61
0.38%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Alzamend Neuro Inc (ALZN)

  7. Alzamend Neuro Inc (ALZN) News

ALZN

Alzamend Neuro (ALZN)

Alzamend Neuro Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALZN
DateTimeSourceHeadlineSymbolCompany
05/10/20244:06PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ALZNAlzamend Neuro Inc
05/10/20243:30PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ALZNAlzamend Neuro Inc
05/10/20245:30AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALZNAlzamend Neuro Inc
05/09/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
05/09/20243:20PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
05/09/20247:00AMBusiness WireAlzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 MillionNASDAQ:ALZNAlzamend Neuro Inc
05/07/20243:31PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALZNAlzamend Neuro Inc
05/07/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
05/07/20247:00AMBusiness WireAlzamend Neuro Announces Termination of At-the-Market Equity Offering ProgramNASDAQ:ALZNAlzamend Neuro Inc
03/07/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
02/02/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
01/05/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
12/15/20233:30PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALZNAlzamend Neuro Inc
12/11/20237:00AMBusiness WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
11/20/20237:00AMBusiness WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
11/16/20233:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
11/16/20237:00AMBusiness WireAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price RequirementNASDAQ:ALZNAlzamend Neuro Inc
11/13/20237:00AMBusiness WireAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001NASDAQ:ALZNAlzamend Neuro Inc
10/30/20233:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
10/30/20237:00AMBusiness WireAlzamend Neuro Announces Reverse Stock SplitNASDAQ:ALZNAlzamend Neuro Inc
10/23/20237:00AMBusiness WireAlzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001NASDAQ:ALZNAlzamend Neuro Inc
10/02/20237:00AMBusiness WireAlzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder PatientsNASDAQ:ALZNAlzamend Neuro Inc
09/29/20233:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
09/26/20235:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALZNAlzamend Neuro Inc
09/22/20233:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
09/22/20237:00AMBusiness WireAlzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing RequirementNASDAQ:ALZNAlzamend Neuro Inc
09/13/20234:09PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALZNAlzamend Neuro Inc
09/08/20234:05PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALZNAlzamend Neuro Inc
09/08/20234:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALZNAlzamend Neuro Inc
09/01/20233:30PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ALZNAlzamend Neuro Inc
 Showing the most relevant articles for your search:NASDAQ:ALZN

Your Recent History

USOTC
SRMX
Saddle Ranch Media (PK)
NASDAQ
RNAZ
TransCode Therapeutics
USOTC
FMCC
Federal Home Loan Mortgage (QB)
NASDAQ
SEV
Sono Group NV
USOTC
FNMA
Fannie Mae (QB)
USOTC
IFUS
Impact Fusion (PK)
USOTC
GVSI
Good Vibrations Shoes (PK)
USOTC
AXXA
Exxe (PK)
USOTC
VPLM
Voip Pal Com (QB)
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
ILST
International Star (PK)
USOTC
AFFU
Affluence (PK)
NASDAQ
COOP
Mr Cooper
NASDAQ
DJT
Trump Media and Technology
COIN
SHIBUSD
SHIBA INU
NASDAQ
AVXL
Anavex Life Sciences
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved